brexit_istock-531915594_altamira83

altamira83 / iStockphoto.com

30 April 2018Big Pharma

UK medicines regulator wants active EU partnership post-Brexit

An “active regulatory partnership” between the UK and the EU is necessary to ensure patients have “timely access” to medicines post-Brexit, according to the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA).

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Life sciences leaders recognised at LSPN Awards USA 2025

UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body

LSPN: Counsel grapple with AI’s impact on training and critical thinking

'Nothing can stand in the way of our work': Ukraine resumes IP system

LSPN: Trump's policy storm causing chaos and confusion

Taylor Wessing expands in Europe with Paris team

LSPN: Using ‘the patentee’s friend’ in Section 112 claims

ResMed voids sleep apnoea tech patent at PTAB